We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Medincell SA (MEDCL) EUR0.5

Sell:€12.36 Buy:€12.90 Change: €0.30 (2.48%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:€12.36
Buy:€12.90
Change: €0.30 (2.48%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:€12.36
Buy:€12.90
Change: €0.30 (2.48%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

Contact details

Address:
3 rue des Freres Lumiere
JACOU
34830
France
Telephone:
+33 (4) 67021367
Website:
https://www.medincell.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MEDCL
ISIN:
FR0004065605
Market cap:
€351.76 million
Shares in issue:
28.72 million
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Philippe Guy
    Independent Chairman of the Supervisory Board
  • Christophe Douat
    Chairman of the Management Board
  • Sabri Markabi
    Independent Vice Chairman of the Supervisory Board
  • Jaime Arango
    Chief Financial Officer, Member of the Management Board
  • Franck Pouzache
    Human Resources Director, Member of the Management Board
  • Stephane Chambaud
    Director of Pharmaceutical Operations
  • Quiterie De Beauregard
    Portfolio Director
  • Sebastien Enault
    Business Development Director
  • Julie Farms
    Legal Director
  • Adolfo Lopez-Noriega
    Director of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.